Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine
The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participan...
Gespeichert in:
Veröffentlicht in: | The Lancet infectious diseases 2019-01, Vol.19 (1), p.e31-e38 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e38 |
---|---|
container_issue | 1 |
container_start_page | e31 |
container_title | The Lancet infectious diseases |
container_volume | 19 |
creator | Wilder-Smith, Annelies Hombach, Joachim Ferguson, Neil Selgelid, Michael O'Brien, Kate Vannice, Kirsten Barrett, Alan Ferdinand, Elizabeth Flasche, Stefan Guzman, Maria Novaes, Hillegonde Maria Ng, Lee-Ching Smith, Peter G Tharmaphornpilas, Piyanit Yoon, In-Kyu Cravioto, Alejandro Farrar, Jeremy Nolan, Terry M |
description | The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses. |
doi_str_mv | 10.1016/S1473-3099(18)30494-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2158515076</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309918304948</els_id><sourcerecordid>2158515076</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-c80986e4e30f3476d095fdb31815d4cafdcf5ddef108ccce840b3f6206001b963</originalsourceid><addsrcrecordid>eNqFkE1PxCAQhonR-P0TNE286KE6CLRwMptdvxITD6smnkgLg2Jsu0K7cf31trvq1RMwPO9M5iHkgMIpBZqdTSnPWcpAqWMqTxhwxVO5Rrb7Mk85F_n68r5CtshOjG8ANKfAN8kWA6qEUmKbVBN89yWGovVNHZPGJe0rJtO2L-CLN8nIzn1swiK5Dk03G_4vP2cY2h6tk9uq6mr_tcwO7yHaRRyo8fMkfZg8JRbrlw6TeWGMr3GPbLjiPeL-z7lLHq8uH8Y36d399e14dJcazqFNjQQlM-TIwDGeZxaUcLZkVFJhuSmcNU5Yi46CNMag5FAyl51D1q9YqoztkqNV31loPjqMrX5rulD3I_U5FVJQAflAiRVlQhNjQKdnwVdFWGgKepCsl5L1YFBTqZeStexzhz_du7JC-5f6tdoDFysA-x3nHoOOxmNt0PqAptW28f-M-AbgTIwD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2158515076</pqid></control><display><type>article</type><title>Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wilder-Smith, Annelies ; Hombach, Joachim ; Ferguson, Neil ; Selgelid, Michael ; O'Brien, Kate ; Vannice, Kirsten ; Barrett, Alan ; Ferdinand, Elizabeth ; Flasche, Stefan ; Guzman, Maria ; Novaes, Hillegonde Maria ; Ng, Lee-Ching ; Smith, Peter G ; Tharmaphornpilas, Piyanit ; Yoon, In-Kyu ; Cravioto, Alejandro ; Farrar, Jeremy ; Nolan, Terry M</creator><creatorcontrib>Wilder-Smith, Annelies ; Hombach, Joachim ; Ferguson, Neil ; Selgelid, Michael ; O'Brien, Kate ; Vannice, Kirsten ; Barrett, Alan ; Ferdinand, Elizabeth ; Flasche, Stefan ; Guzman, Maria ; Novaes, Hillegonde Maria ; Ng, Lee-Ching ; Smith, Peter G ; Tharmaphornpilas, Piyanit ; Yoon, In-Kyu ; Cravioto, Alejandro ; Farrar, Jeremy ; Nolan, Terry M</creatorcontrib><description>The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(18)30494-8</identifier><identifier>PMID: 30195995</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Adolescent ; Age groups ; Child ; Child, Preschool ; Cost analysis ; Dengue fever ; Dengue hemorrhagic fever ; Dengue Vaccines - adverse effects ; Dengue Vaccines - immunology ; Dengue Virus - immunology ; Diagnostic systems ; Disease ; Female ; Humans ; Immunization ; Immunization, Secondary ; Infections ; Infectious diseases ; Licenses ; Male ; Mass Screening ; Population ; Public health ; Schedules ; Screening ; Seroepidemiologic Studies ; Serology ; Severe Dengue - prevention & control ; Severe Dengue - virology ; Treatment Outcome ; Vaccination ; Vaccines ; Vaccines, Attenuated - immunology ; Vector-borne diseases ; Working groups ; World Health Organization</subject><ispartof>The Lancet infectious diseases, 2019-01, Vol.19 (1), p.e31-e38</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-c80986e4e30f3476d095fdb31815d4cafdcf5ddef108ccce840b3f6206001b963</citedby><cites>FETCH-LOGICAL-c440t-c80986e4e30f3476d095fdb31815d4cafdcf5ddef108ccce840b3f6206001b963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309918304948$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30195995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilder-Smith, Annelies</creatorcontrib><creatorcontrib>Hombach, Joachim</creatorcontrib><creatorcontrib>Ferguson, Neil</creatorcontrib><creatorcontrib>Selgelid, Michael</creatorcontrib><creatorcontrib>O'Brien, Kate</creatorcontrib><creatorcontrib>Vannice, Kirsten</creatorcontrib><creatorcontrib>Barrett, Alan</creatorcontrib><creatorcontrib>Ferdinand, Elizabeth</creatorcontrib><creatorcontrib>Flasche, Stefan</creatorcontrib><creatorcontrib>Guzman, Maria</creatorcontrib><creatorcontrib>Novaes, Hillegonde Maria</creatorcontrib><creatorcontrib>Ng, Lee-Ching</creatorcontrib><creatorcontrib>Smith, Peter G</creatorcontrib><creatorcontrib>Tharmaphornpilas, Piyanit</creatorcontrib><creatorcontrib>Yoon, In-Kyu</creatorcontrib><creatorcontrib>Cravioto, Alejandro</creatorcontrib><creatorcontrib>Farrar, Jeremy</creatorcontrib><creatorcontrib>Nolan, Terry M</creatorcontrib><title>Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.</description><subject>Adolescent</subject><subject>Age groups</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cost analysis</subject><subject>Dengue fever</subject><subject>Dengue hemorrhagic fever</subject><subject>Dengue Vaccines - adverse effects</subject><subject>Dengue Vaccines - immunology</subject><subject>Dengue Virus - immunology</subject><subject>Diagnostic systems</subject><subject>Disease</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Licenses</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Population</subject><subject>Public health</subject><subject>Schedules</subject><subject>Screening</subject><subject>Seroepidemiologic Studies</subject><subject>Serology</subject><subject>Severe Dengue - prevention & control</subject><subject>Severe Dengue - virology</subject><subject>Treatment Outcome</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vector-borne diseases</subject><subject>Working groups</subject><subject>World Health Organization</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkE1PxCAQhonR-P0TNE286KE6CLRwMptdvxITD6smnkgLg2Jsu0K7cf31trvq1RMwPO9M5iHkgMIpBZqdTSnPWcpAqWMqTxhwxVO5Rrb7Mk85F_n68r5CtshOjG8ANKfAN8kWA6qEUmKbVBN89yWGovVNHZPGJe0rJtO2L-CLN8nIzn1swiK5Dk03G_4vP2cY2h6tk9uq6mr_tcwO7yHaRRyo8fMkfZg8JRbrlw6TeWGMr3GPbLjiPeL-z7lLHq8uH8Y36d399e14dJcazqFNjQQlM-TIwDGeZxaUcLZkVFJhuSmcNU5Yi46CNMag5FAyl51D1q9YqoztkqNV31loPjqMrX5rulD3I_U5FVJQAflAiRVlQhNjQKdnwVdFWGgKepCsl5L1YFBTqZeStexzhz_du7JC-5f6tdoDFysA-x3nHoOOxmNt0PqAptW28f-M-AbgTIwD</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Wilder-Smith, Annelies</creator><creator>Hombach, Joachim</creator><creator>Ferguson, Neil</creator><creator>Selgelid, Michael</creator><creator>O'Brien, Kate</creator><creator>Vannice, Kirsten</creator><creator>Barrett, Alan</creator><creator>Ferdinand, Elizabeth</creator><creator>Flasche, Stefan</creator><creator>Guzman, Maria</creator><creator>Novaes, Hillegonde Maria</creator><creator>Ng, Lee-Ching</creator><creator>Smith, Peter G</creator><creator>Tharmaphornpilas, Piyanit</creator><creator>Yoon, In-Kyu</creator><creator>Cravioto, Alejandro</creator><creator>Farrar, Jeremy</creator><creator>Nolan, Terry M</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>201901</creationdate><title>Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine</title><author>Wilder-Smith, Annelies ; Hombach, Joachim ; Ferguson, Neil ; Selgelid, Michael ; O'Brien, Kate ; Vannice, Kirsten ; Barrett, Alan ; Ferdinand, Elizabeth ; Flasche, Stefan ; Guzman, Maria ; Novaes, Hillegonde Maria ; Ng, Lee-Ching ; Smith, Peter G ; Tharmaphornpilas, Piyanit ; Yoon, In-Kyu ; Cravioto, Alejandro ; Farrar, Jeremy ; Nolan, Terry M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-c80986e4e30f3476d095fdb31815d4cafdcf5ddef108ccce840b3f6206001b963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Age groups</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cost analysis</topic><topic>Dengue fever</topic><topic>Dengue hemorrhagic fever</topic><topic>Dengue Vaccines - adverse effects</topic><topic>Dengue Vaccines - immunology</topic><topic>Dengue Virus - immunology</topic><topic>Diagnostic systems</topic><topic>Disease</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Licenses</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Population</topic><topic>Public health</topic><topic>Schedules</topic><topic>Screening</topic><topic>Seroepidemiologic Studies</topic><topic>Serology</topic><topic>Severe Dengue - prevention & control</topic><topic>Severe Dengue - virology</topic><topic>Treatment Outcome</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vector-borne diseases</topic><topic>Working groups</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilder-Smith, Annelies</creatorcontrib><creatorcontrib>Hombach, Joachim</creatorcontrib><creatorcontrib>Ferguson, Neil</creatorcontrib><creatorcontrib>Selgelid, Michael</creatorcontrib><creatorcontrib>O'Brien, Kate</creatorcontrib><creatorcontrib>Vannice, Kirsten</creatorcontrib><creatorcontrib>Barrett, Alan</creatorcontrib><creatorcontrib>Ferdinand, Elizabeth</creatorcontrib><creatorcontrib>Flasche, Stefan</creatorcontrib><creatorcontrib>Guzman, Maria</creatorcontrib><creatorcontrib>Novaes, Hillegonde Maria</creatorcontrib><creatorcontrib>Ng, Lee-Ching</creatorcontrib><creatorcontrib>Smith, Peter G</creatorcontrib><creatorcontrib>Tharmaphornpilas, Piyanit</creatorcontrib><creatorcontrib>Yoon, In-Kyu</creatorcontrib><creatorcontrib>Cravioto, Alejandro</creatorcontrib><creatorcontrib>Farrar, Jeremy</creatorcontrib><creatorcontrib>Nolan, Terry M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilder-Smith, Annelies</au><au>Hombach, Joachim</au><au>Ferguson, Neil</au><au>Selgelid, Michael</au><au>O'Brien, Kate</au><au>Vannice, Kirsten</au><au>Barrett, Alan</au><au>Ferdinand, Elizabeth</au><au>Flasche, Stefan</au><au>Guzman, Maria</au><au>Novaes, Hillegonde Maria</au><au>Ng, Lee-Ching</au><au>Smith, Peter G</au><au>Tharmaphornpilas, Piyanit</au><au>Yoon, In-Kyu</au><au>Cravioto, Alejandro</au><au>Farrar, Jeremy</au><au>Nolan, Terry M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2019-01</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>e31</spage><epage>e38</epage><pages>e31-e38</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>30195995</pmid><doi>10.1016/S1473-3099(18)30494-8</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1473-3099 |
ispartof | The Lancet infectious diseases, 2019-01, Vol.19 (1), p.e31-e38 |
issn | 1473-3099 1474-4457 |
language | eng |
recordid | cdi_proquest_journals_2158515076 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adolescent Age groups Child Child, Preschool Cost analysis Dengue fever Dengue hemorrhagic fever Dengue Vaccines - adverse effects Dengue Vaccines - immunology Dengue Virus - immunology Diagnostic systems Disease Female Humans Immunization Immunization, Secondary Infections Infectious diseases Licenses Male Mass Screening Population Public health Schedules Screening Seroepidemiologic Studies Serology Severe Dengue - prevention & control Severe Dengue - virology Treatment Outcome Vaccination Vaccines Vaccines, Attenuated - immunology Vector-borne diseases Working groups World Health Organization |
title | Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A24%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deliberations%20of%20the%20Strategic%20Advisory%20Group%20of%20Experts%20on%20Immunization%20on%20the%20use%20of%20CYD-TDV%20dengue%20vaccine&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Wilder-Smith,%20Annelies&rft.date=2019-01&rft.volume=19&rft.issue=1&rft.spage=e31&rft.epage=e38&rft.pages=e31-e38&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(18)30494-8&rft_dat=%3Cproquest_cross%3E2158515076%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2158515076&rft_id=info:pmid/30195995&rft_els_id=S1473309918304948&rfr_iscdi=true |